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Missense mutations in the 30 end of the p63 gene are associated with either RHS (Rapp-Hodgkin syndrome) or
AEC (Ankyloblepharon Ectodermal defects Cleft lip/palate) syndrome. These mutations give rise to mutant
p63a protein isoforms with dominant effects towards their wild-type counterparts. Here we report four
RHS/AEC-like patients with mutations (p.Gln9fsX23, p.Gln11X, p.Gln16X), that introduce premature termi-
nation codons in the N-terminal part of the p63 protein. These mutations appear to be incompatible with
the current paradigms of dominant-negative/gain-of-function outcomes for other p63 mutations. Moreover
it is difficult to envisage how the remaining small N-terminal polypeptide contributes to a dominant disease
mechanism. Primary keratinocytes from a patient containing the p.Gln11X mutation revealed a normal and
aberrant p63-related protein that was just slightly smaller than the wild-type p63. We show that the smaller
p63 protein is produced by translation re-initiation at the next downstream methionine, causing truncation
of a non-canonical transactivation domain in the DN-specific isoforms. Interestingly, this new DDNp63 iso-
form is also present in the wild-type keratinocytes albeit in small amounts compared with the p.Gln11X
patient. These data establish that the p.Gln11X-mutation does not represent a null-allele leading to haplo-
insufficiency, but instead gives rise to a truncated DNp63 protein with dominant effects. Given the nature
of other RHS/AEC-like syndrome mutations, we conclude that these mutations affect only the DNp63a
isoform and that this disruption is fundamental to explaining the clinical characteristics of these particular
ectodermal dysplasia syndromes.
INTRODUCTION
p53 Protein and its evolutionary predecessors p63 and p73
constitute a family of key transcriptional regulators in cell
growth, differentiation and apoptosis. While p53 is a major
player in tumorigenesis, p63 and p73 appear to have pivotal
roles in embryonic development. p73-Deficient mice have
neurological and inflammatory problems, whereas
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p63-knockout mice have major defects in epithelial, limb and
craniofacial development (1–3). These observations suggest
that p63 has a crucial role in tissue morphogenesis and main-
tenance of epithelial stem cell compartments. Furthermore,
p63 has been linked to several important signaling pathways,
such as epidermal growth factor (EGF), fibroblast growth
factor (FGF), bone morphogenetic protein (BMP), and
Notch, Wnt (wingless-type) and Hedgehog (4–9).
The p63 gene consists of 16 exons located on chromosome
3q28. At least six different protein isoforms can be produced,
due to two different promoter sites and three different splicing
routes. The amino-terminal ends are called TA and DN, and at
the carboxy-terminal end, a, b and g termini can be syn-
thesized (Fig. 1). Several functional domains have been identi-
fied. The central DNA-binding domain and isomerization
domain are present in all p63 isoforms. The canonical tran-
scription activation (TA) domain is located at the amino-
terminal end of the TAp63 isoforms. The DN-isoforms also
contain an amino-terminal transactivation domain, denoted
TA2 (10,11). The carboxy-terminal end has two additional
domains: the sterile-alpha-motif (SAM) domain and a trans-
activation inhibitory (TI) domain, which are both only
present in the largest carboxy-terminal variant, p63a (12).
Heterozygous mutations in the human p63 gene cause
developmental disorders, characterized by various combi-
nations of ectodermal dysplasia (ED), limb malformations
and orofacial clefting (13,14). To date, seven different dis-
orders have been linked to mutations in the p63 gene (15).
These conditions may have overlapping phenotypic features,
but some genotype–phenotype correlations have emerged
(16). EEC syndrome (Ectrodactyly Ectodermal dysplasia and
Cleft lip/palate, OMIM 604292) is the most common
p63-linked ED. It is characterized by three major clinical
symptoms: cleft lip and/or palate, ED (abnormal teeth, skin,
hair, nails and sweat glands) and limb malformations in the
form of split hand/foot (ectrodactyly) and/or fusion of
fingers/toes (syndactyly). About 10% of p63-linked patients
have Rapp-Hodgkin syndrome (RHS) (OMIM 129400) or
AEC (Ankyloblepharon Ectodermal defects Cleft lip/palate)/
Hay-Wells syndrome (OMIM 106260). These two latter syn-
dromes fulfill the criteria of ED and orofacial clefting, but
do not have the severe limb malformations seen in EEC syn-
drome. Some typical characteristics linked to RHS/AEC-like
syndromes are eyelid fusion (ankyloblepharon filiforme
adnatum), severe skin erosion at birth and abnormal hair
with pili torti or pili canaliculi. Indeed, RHS and AEC syn-
dromes are very similar and have been suggested to be vari-
able manifestations of the same clinical entity (15,17). EEC
and RHS/AEC syndromes are good examples of a strong gen-
otype–phenotype association. Mutations in the EEC syndrome
are clustered in the DNA binding domain, and most likely alter
the DNA-binding properties of the protein. In contrast,
mutations in RHS/AEC syndromes are clustered in SAM
and TI domains in the carboxy-terminus of p63a (15–29).
The SAM domain is involved in protein-protein interactions,
whereas the TI-domain can bind intra-molecularly to the
TA-domain, thereby inhibiting transcription activation
(12,30). All p63-linked disorders are inherited in an autosomal
dominant manner and mutations are thought to have either
dominant-negative or gain-of-function effects (31).
In this article we describe four patients from three families
with phenotypes consistent with RHS/AEC syndromes that
result from atypical nonsense mutations (p.Gln11X,
p.Gln16X) or a deletion mutation (p.Gln9fsX23), all of
which lead to a premature termination codon (PTC) in the
early amino-terminal end of the DNp63-isoforms. These
mutations are predicted to give rise to a null allele, which con-
tradicts the accepted disease mechanism of other mutations.
Surprisingly, in keratinocytes from the patient with the
p.Gln11X mutation we were able to detect normal p63 RNA
levels of both alleles, but also an additional smaller protein
product. Using molecular studies we could demonstrate that
the smaller p63 protein was produced by translational
re-initiation at the next methionine after the PTC. This
causes a deletion of 25 amino acids in the DNp63-isoforms,
abrogating the TA2 domain, and thus suggesting a crucial
role for this part of p63 in the pathogenesis of RHS/AEC
syndromes.
RESULTS
Identification of atypical mutations predicting
N-terminal premature stop codons
We identified four patients in three families with a clinical
presentation reminiscent of AEC/RHS-like ED syndrome
(for details see Materials and Methods). Direct sequencing
of all 16 exons of the p63 gene revealed three different hetero-
zygous nucleotide changes in affected individuals. In family 1,
both mother and daughter have a nucleotide change c.31C.T
(Fig. 2A) (accession number AF075431) in the first coding
exon, the alternative exon 30, that is present only in the
DNp63 isoform. The c.31C.T mutation changes glutamine
to a stop codon at amino acid position 11, creating a PTC in
all DNp63 isoforms. In family 3, a deletion of one nucleotide
(c.26delA) was identified (Fig. 2B), also located in the alterna-
tive exon 30 of DNp63 isoforms. This causes a frameshift and
a PTC 41 nt downstream from the deletion (Fig. 2E). In family
2, a nucleotide change c.46C.T was detected in exon 4
(Fig. 2C). This mutation causes a change of glutamine to a
stop codon at amino acid position 16 in the DNp63 isoforms
and at position 71 in TAp63 isoforms. The genomic change
Figure 1. Schematic overview of the p63 gene and two of its protein products.
(A) p63 has two different promoter sites resulting in two different N-terminal
ends called TA and DNp63. DNp63 lacks the exons 1–3, which are present in
TA, however it contains an alternative exon 30. p63 has three C-terminal spli-
cing routes: a, b and g, thus at least six different gene products can be tran-
scribed. (B) The domain structure of TA and DNp63 is similar, only
N-terminal transactivation domain is different, called TA and TA2, respect-
ively. Domain abbreviations: ISO (isomerization domain), SAM
(sterile-alpha-motif domain) and TID (transactivation inhibitory domain).
The numbering under the domains illustrates the amino acid positions.
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c.46C.T (or c.211C.T in TAp63 accession number
AF075430) indicates a PTC in both DN and TAp63 isoforms.
These three mutations were not identified in DNA from any of
the unaffected family members nor in 300 control DNAs, indi-
cating that they are all pathogenic, resulting in RHS/AEC-like
syndromes.
Harmful and deleterious transcripts with a PTC are usually
degraded through nonsense-mediated decay (NMD). In
general, all transcripts containing a PTC upstream of the last
exon junction complex are recognized and degraded (32). The
c.31C.T mutation is present in the first exon of DNp63 fol-
lowed by 11 exon junctions and c.26delA causes a PTC in the
second exon (exon 4), followed by 10 exon junctions.
c.46C.T (c.211C.T) causes a PTC in the second exon of
DNp63 and in the fourth exon of TAp63, in both cases following
10 exon junctions. According to this paradigm, the transcripts
with PTCs caused by these mutations should all be degraded
by NMD and thereby cause p63 haploinsufficiency.
To investigate this phenomenon in more detail we obtained
a skin biopsy from the affected mother of family 1 and estab-
lished a keratinocyte culture. p63 RNA expression levels in
cultured keratinocytes were determined by quantitative PCR
(qPCR) using two different primer sets specific for the 50
end encoding DN-isoforms and one primer set for the 30 end
of the a-isoforms. All these three primer sets gave similar
Ct-values suggesting that the major isoform in normal
control keratinocytes is DNp63a (data not shown). Surpris-
ingly, p63 RNA expression levels in cultured keratinocytes
from the patient with the p.Gln11X mutation were similar to
those of controls (Fig. 3), which refutes the p63 haploinsuffi-
ciency model. We then sequenced the amplified RT-PCR
products, which revealed that the nucleotide change
c.31C.T was also present in the keratinocyte RNA pool.
The presence of both alleles (Fig. 2D) argues against NMD.
N-terminal truncation of DNp63a due to translational
re-initiation
Having established that the nonsense mutations do not have an
effect on the mutant transcript levels, we next determined the
consequences of the N-terminal mutations at the protein level.
Western blot analysis performed on protein extracts from the
patient’s cultured keratinocytes with an antibody specific to
the a-tail of p63, revealed an additional DNp63 protein of
reduced molecular weight (3 kDa). A band of similar size
was also present at very low levels in keratinocytes from
control individuals, shown with the p63a-specific antibody
in the western blot in Figure 4A. To resolve the identity of
the smaller protein product, we investigated the nucleotide
sequence downstream of the mutation. A further ATG codon
was identified 44 nt downstream of the c.31C.T mutation
(Fig. 2E). This is the first ATG codon following the canonical
DN start codon and is located 75 nt downstream in the same
reading frame. The Kozak sequence flanking this second
AUG is in accordance with a strong translation initiation
sequence, stronger even than the first AUG codon (Fig. 2E)
(33,34). In addition, a translation start prediction program esti-
mated this AUG to be an initiation site at score 0.631, a value
within normal range of bonafide translation (Netstart 1.0 Pre-
diction Server). We hypothesized that the next methionine
downstream of the p.Gln11X mutation will be used to reiniti-
ate the translation. A similar mechanism to escape NMD has
been demonstrated previously for nonsense or frameshift
mutations in BRCA1, ATP7A and NEMO genes (35–39).
To provide further support for the translation re-initiation
hypothesis, we performed transfection studies in p63 negative
Saos-2 cells. We performed transient transfections with a full-
length DNp63a cDNA under a constitutive CMV promoter,
pcDNA3_CMV_DNp63a. After transfections, the expression
of each construct was confirmed by immunofluorescent label-
ing (data not shown). Protein lysate of each transfection was
analyzed by western blotting. Firstly, we mutated the second
methionine at position 26 to isoleucine to investigate
whether this methionine is involved in translation initiation
of the smaller DNp63a fragment. Wild-type DNp63a is
Figure 2. Pathogenic mutations in three RHS/AEC syndrome families. Direct
sequencing of genomic DNA from four AEC/RHS patients revealed N-
terminal mutations in the p63 gene. (A) In family 1 a heterozygous nucleotide
change c.31C.T was found in affected mother and daughter in exon 30. The
upper chromatogram illustrates a control sequence and the lower is from the
affected mother. (B) In family 3, a heterozygous deletion c.26delA was
detected in the index patient in exon 30. The upper sequence is a control
and the lower is from the patient. (C) In family 2 a heterozygous nucleotide
change c.46C.T (DNp63-isoform) was detected in exon 4 in the index
patient. The upper chromatogram illustrates a control DNA sequence and
the lower is from the patient. (D) Chromatogram of the sequenced cDNA of
keratinocytes from the mother of family 1 reveals the same heterozygous
nucleotide change detected in the genomic DNA (Fig. 3A). Mutated RNA is
present in the cells and is not degraded by the nonsense mediated RNA
decay as expected. (E) The translated sequence of DNp63a (AF075431) (capi-
tals) contains two AUG sites (bold, underlined) in the two first exons (exon 30
and 4, j indicates the exon boundary). The mutated nucleotides: c.26A, c.31C
and c.46C (indicated red and bold) are located between these two initiation
sites. c.26delA mutation leads to a frameshift, which causes a PTC (indicated
by ) only 5 nt upstream of the second AUG site. c.31C.T changes the
codon CAA into a termination codon TAA (this PTC is 44 nt upstream
from the second AUG). c.46C.T changes codon CAG into a termination
codon TAG causing a PTC 29 nt upstream of the second AUG. The second
initiation codon is flanked by a strong Kozak sequence, where the most
important nucleotides (purine at position –3 and a guanine at position þ4)
are conserved suggesting its use in translation re-initiation.
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present in two protein bands, however, when methionine at
position 26 is mutated, only the full-length DNp63a protein
was present (Fig. 4B) and the smaller protein variant was
undetectable, even upon high over-exposure of the blot. Sec-
ondly, all three pathogenic mutations (p.Gln11X, p.Gln16X
and p.Gln9fsX23) and double mutants (p.Gln11X_Met26Ile,
p.Gln16X_Met26Ile, p.Gln9fsX23_Met26Ile) were introduced
into the DNp63a constructs. The transfection studies demon-
strated a molecular size reduction (3 kDa) after introduction
of the p.Gln11X, p.Gln16X or p.Gln9fsX23 mutation into cells
(Fig. 4C), which is accordance with the additional protein
observed in the patient’s keratinocytes (Fig. 4A). Finally,
when introducing the double mutant p.Met26Ile in combi-
nation with each pathogenic mutation, none of the two
protein variants were detected (Fig. 4C). This strongly
suggests that methionine 26 is used to initiate the translation
of DDNp63a in the presence of mutations that cause upstream
premature stop codons. The shorter protein variant DDNp63a
was also detected in cells transfected with wild-type DNp63a,
but at lower levels than the full-length protein. This pheno-
menon is similar to keratinocytes from control individuals,
although the shorter variant is present in much lower levels
compared with transfected cells.
Transcriptionally inactive DDNp63a
The protein analysis showed that the p.Gln11X mutation
causes an amino-terminal deletion of 25 amino acids. To
study the transactivational activity of the DNp63 amino-
terminus, we tested a series of truncation mutations in the
DNp63g isoform (D14, D26, D43, D61, D79) for transactiva-
tion activity (Fig. 5A). Full-length DNp63g was able to acti-
vate an optimized p53 promoter nearly 6-fold more than the
empty vector. In contrast, truncation of the first 14 amino
acids completely abolished the activation (Fig. 5B). The same
inactivating effect was detected for all other truncation
mutations. Thus, 14 unique amino acids at the DN-terminus of
p63 constitute a functional domain, which has transactivational
Figure 3. DNp63a levels in cultured keratinocytes from a Rapp-Hodgkin syn-
drome patient. DNp63 and p63a expression levels are investigated in undiffer-
entiated keratinocytes by qPCR. The control (dark gray bar) is a pool of five
control samples and the RHS patient sample (light gray bar) is from the mother
of family 1 containing the p.Gln11X mutation. Housekeeping genes ACTB,
GAPDH and hARP were used in normalization. qPCR with two DNp63
specific primer sets (A and B) show that DNp63 expression in RHS sample
is very similar to the control, indicating that RNA containing the mutation
is not degraded by NMD as expected. qPCR with p63a specific primer set
gives similar results than DNp63 specific primer sets (C). Furthermore,
similar Ct-values (data not shown) indicate DNp63a to be the only isoform
expressed in undifferentiated cultured keratinocytes.
Figure 4. An additional DNp63a protein product in Rapp-Hodgkin syndrome
patient is caused by translational re-initiation at methionine 26. (A) The lysate
of cultured keratinocytes was run on NuPAGEwBis–Tris Pre Cast Gels
System. p63a-specific antibody H-129 [Santa Cruz] was used to detect the
signal on nitrocellulose membrane. This experiment demonstrates two
DNp63a protein variants in cultured keratinocytes. In control samples (lanes
1 and 2), the smaller DNp63a variant is present in small quantities.
However, in the Rapp-Hodgkin syndrome sample (lane 3) the ratio is about
one to one. a-tubulin [Abcam] is used as a loading control. (B) The second
putative initiation site in DNp63, methionine 26, was mutated to isoleucine
in a wild-type expression vector and transiently transfected into p63 negative
Saos-2 cells, and harvested 30–48 h after transfection. The cell lysates were
run on 8% SDS-Polyacrylamide gel and blotted to a nitrocellulose membrane.
This was incubated with p63a-specific antibody H129 [Santa Cruz]. Mock
(lane 1) is negative. When transfecting the wild-type DNp63a (lane 2) two
p63 products are clearly present. However, when transfecting the mutation
construct (Met26 is mutated into isoleucine), the lower product is missing
(lane 3). This indicates that methionine at position 26 can initiate the trans-
lation. (C) N-terminal RHS and AEC mutations were also introduced to the
expression vector along with the vector containing the Met26Ile mutation.
These constructs were transfected into the Saos-2 cells and prepared as
described above. Lane 1 contains empty vector pcDNA3. Wild-type
DNp63a (lane 2) produces the double band similar to 4B. However, when
transfecting the pathogenic mutations p.Gln11X (lane 3), p.Gln16X (lane 5)
and p.Gln9fsX23 (lane 7) the upper product is completely absent. When a
combination of pathogenic mutation plus a Met26Ile mutation is present
[p.Gln11X_Met26Ile (lane 4), p.Gln16X_Met26Ile (lane 6) and
p.Gln9fsX23_p.Met26Ile (lane 8)] no p63a protein product is detected at
all. This experiment clearly demonstrates that all three pathogenic mutations
cause translational re-initiation at methionine 26.
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activity. This is in accordance with previous studies on other
promoters (10,11,40).
Because DNp63a is the predominant isoform in keratino-
cytes, we set out to test the ability of the p.Gln9fsX23,
p.Gln11X and p.Gln16X mutants to regulate downstream
target genes. Keratin-14 (K14) was recently reported to be
a natural target gene of p63, which is upregulated by
DNp63a (40–42). A transactivation assay of p63-negative
Saos-2 cells transfected with either DNp63a wild-type,
mutant or a combination of these constructs, together with a
K14-luciferase-reporter construct, revealed that wild-type
DNp63a was able to activate the K14 promoter 2.5 times
more than the empty vector. This is in contrast to all
DNp63a mutant constructs (p.Gln9fsX23, p.Gln11X and
p.Gln16X), which were inactive and behaved similar to
empty vectors (Fig. 5C). Co-transfections of each single
mutation in combination with DNp63a wild-type vector
showed no increased K14-promoter activation (Fig. 5C),
indicating a dominant effect of these mutations against the
wild-type. Next we investigated whether the mechanism of
action of the mutant DNp63a protein might be dose dependent.
To that end, we co-transfected Saos-2 cells with the wild-type
and mutant constructs in a 5:1, 1:1 and 1:5 ratio (Fig. 5D).
The 5:1 ratio of wild-type and p.Gln11X mutant was able to
activate the K14-promoter 2.3-fold, which is similar to the
wild-type DNp63a activation. In contrast, when we increased
the amount of mutant p.Gln11X construct the activation was
reduced to 1.2 and 0.8 in 1:1 and 1:5 ratios, respectively, indi-
cating a dose-dependent inhibitory activity. Finally, we tested
the dominant effect of mutant DNp63a_Gln11X towards
TAp63g isoform (Fig. 5E). DNp63a wild-type can inhibit
the TAp63g activation from 35-fold to 5-fold when com-
pared with empty vector. The mutated DNp63a_Gln11X has
a similar inhibitory activity as the wild-type DNp63a, indicat-
ing that the mutated protein can bind to DNA. These results
show that mutant DNp63a isoforms have dominant effects
towards various wild-type p63 isoforms and that they are dose-
dependent.
Figure 5. Transactivational activity in the N-terminus of DNp63 isoform. (A) Multiple sequence alignment represents the conservation of N-terminus of DNp63:
all three glutamines mutated in RHS/AEC patients and the putative second translational initiation codon Met26 are almost fully conserved. The N-terminal trun-
cation mutations are also indicated in this alignment. (B) Saos-2 cells were transiently transfected with N-terminally truncated p63 cDNA expression vectors
(shown in Fig. 5A) and p53 promoter activation was measured. The truncated proteins lack the N-terminal 14 amino acids (D14, i.e. the residues which are
unique for DNp63 isoforms) or N-terminal 26, 43, 61 or 79 amino acids (D26, D43, D61, D79, respectively). Full-length DNp63g can activate the p53 promoter
6-fold, whereas deleting the first 14, 26, 43, 61 or 79 amino acids abrogates the transactivational activity completely. (C) Saos-2 cells were transfected with
empty vector (pcDNA3), DNp63a wild-type, DNp63a mutant (p.Gln9fsX23, p.Gln11X and p.Gln16X) or combination of wild-type and mutant, and K14 pro-
moter activation was then measured. The wild-type DNp63a is able to activate the K14 promoter 2.5 times, whereas none of the DNp63a mutants is able to
activate the promoter at all. Neither co-transfection of wild-type and mutant are able to activate K14 promoter, indicating a dominant negative effect for the
mutants. (D) Saos-2 cells were transfected with wild-type and p.Gln11X DNp63a constructs in different ratios and K14 promoter activity was measured. 5:1
ratio of DNp63a wild-type and p.Gln11X can activate K14 promoter similar to DNp63a wild-type construct, however, when using 1:1 or 1:5 ratio, which
mimics RHS patient situation the activation is repressed and is similar to p.Gln11X construct. This supports the hypothesis that DDNp63a is a dose-dependent
regulator of DNp63a. (E) Finally, Saos-2 cells were transfected with TAp63g and DNp63a isoforms. Wild-type TAp63g can activate the p53-promoter 34 times
when comparing with empty vector, whereas DNp63a cannot activate the promoter at all. Instead, DNp63a wild-type inhibits the activity of TAp63g in a
co-transfection assay. This dominant negative effect against the TAp63g is also detected in the RHS p.Gln11X DNp63a, indicating that the mutated molecule
is able to bind to the promoter.
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DISCUSSION
Until now, mutations causing RHS and AEC syndrome have
only been described in exons 13 and 14, which encode the
SAM and TI domains of the p63a-protein. Here we report
three RHS/AEC families without any changes in these
exons, but with novel pathogenic mutations in the amino-
terminus of DNp63: p.Gln9fsX23 and p.Gln11X (in the
alternative exon 30) and p.Gln16X (in exon 4). The first two
are present in only the DNp63 isoforms, whereas the latter is
present in both DNp63 and TAp63 isoforms. All these
mutations lead to PTCs soon after the first translation initiation
codon. Despite this, these mutant alleles still produce a
p63-related protein by re-initiation of translation at the next
ATG codon. Recently, similar translation re-initiation pro-
cesses have been reported in genes causing other human inher-
ited diseases, such as breast cancer, Menkes disease and
Incontinentia pigmenti (36–39). Nevertheless, this is the first
time that altered N-terminus and translation re-initiation has
been linked to p63 and RHS/AEC syndromes.
The mutations reported here are not associated with severe
skin phenotype. Absence of skin defects is also observed in
60% RHS and 20% of AEC syndrome patients (28). Since
we have studied only four patients, it cannot be concluded
whether the lack of severe skin defects is related to the posi-
tion of the mutations or just a reflection of the normal clinical
variety in RHS/AEC. The three novel mutations we have
reported are of particular interest, as they differ completely
from the previously identified mutations in Rapp-Hodgkin
and AEC syndromes. The 23 pathogenic mutations reported
so far in p63 in these disorders are missense mutations, dele-
tions or insertions clustered in the a-terminus of p63, chan-
ging the composition of the SAM and TI domains (15–29).
However, our new findings, based on the sites of the
p.Gln11X, p.Gln16X and p.Gln9fsX23 mutations, imply that
DNp63a is the critical isoform causing RHS/AEC syndrome.
One of the new mutations we report (p.Gln16X/p.Gln71X)
also affects the TA-isoform, although since DNp63a is the
only p63 isoform (.99%) expressed in epithelial tissues, the
relevance of TA-isoform disruption remains obscure (8,40).
Moreover, the phenotype of the patient carrying the
p.Gln16X/p.Gln71X mutation is not significantly different
from that of the patients with the other mutations in families
1 and 3. This strongly indicates that either an aberrant DN-
or a-terminus of p63 cause a condition which is character-
ized by ED and orofacial clefting, but not developmental
limb problems.
It has been shown previously that DNp63a can function
both as an activator and a repressor of transcription
(10,40,43–45). We tested transactivational activity of
p.Gln9fsX23, p.Gln11X and p.Gln16X in a transactivation
assay on the K14 promoter, on which DNp63a acts as an acti-
vator of transcription. Mutant constructs are unable to activate
the K14 promoter (Fig. 5C), indicating that the first 25 amino
acids are crucial for the activation. This is in accordance with
the results of transactivation assays in this paper (Fig. 5B), in
which deletion mutants affect the N-terminal TA2 domain.
In addition, in previous assays the N-terminal deletion abro-
gates the activity to transactivate p53 target genes and
induce cell cycle arrest and apoptosis (10,11). Our TAp63g
co-transfection assay show that the p.Gln11X mutant can
inhibit TAp63g-mediated transactivation (Fig. 5E), indicating
that this mutant is able to bind to DNA and form heteromers
with other p63 isoforms. Previously, we have demonstrated
that the SAM domain mutant proteins have lost their ability
to form p63-protein complexes and their ability to bind to
DNA (18). Apparently, the DN-mutant proteins have retained
these properties. It is unclear whether these properties have an
effect on the phenotype since they are highly similar, except
perhaps for the skin phenotype, which is not severe in the
patients with N-terminal mutation. In addition, the DNp63a
co-transfection assay shows that all these three mutants
can inhibit DNp63a wild-type transactivation (Fig. 5C),
suggesting that these mutations have a dominant negative
effect.
The first 25 amino acids in the DNp63a are crucial for the
correct function of the DNp63-isoforms. The shorter
DDNp63a variant was also detected in wild-type keratinocytes
as well as in DNp63a-transfected Saos-2 cells (Fig. 4). In ker-
atinocytes, this new isoform appears to be more abundant than
any other p63 isoform (TA, b, g) except DNp63a. This indi-
cates that the p63 gene encodes more protein isoforms than
the six that have been recognized to date (Fig. 1). Therefore,
this p63 variant appears to be a novel translational variant
and apparently not deleterious for the cells. We hypothesize
that in keratinocytes the DDNp63a isoform has a regulatory
function, which is imbalanced in patients because of the
increased amount of DDNp63a. Our dose-dependent assay
of DNp63a and DDNp63a on K14 promoter also showed
that elevated amount of DDNp63a represses the DNp63a acti-
vation (Fig. 5D). Thus, the disturbed ratio between the full-
length and shorter p63 variant might be relevant for causing
the disease phenotype. Since AEC/RHS is a dominantly inher-
ited disease, we propose a dominant-negative effect of the
DDN-isoform against wild-type DN-isoform in either a
dimer or tetramer structure. Once the mutated and wild-type
isoform form a functional protein complex, the DDN-isoform
may alter the function of this complex, working as a repressor
or an activator.
Both DN- and a-terminal mutations can lead to a highly
similar clinical phenotype, although the molecular mechan-
isms involved in the pathogenesis are as yet unknown. The
TI-domain of the a-terminus intra-molecularly binds to the N-
terminal TA-domain, even though this has not been reported
for the DN-terminus of DNp63a (12). It appears however,
that both types of mutations have an effect on transcription
regulation by DNp63a. Here we have shown that deletions
of DNp63 result in reduced transactivation activity by
DNp63a on p53 and p63 promoters. Previously we have
shown that SAM-domain mutants ablate the transactivational
inhibitory effects of DNp63a towards transactivation by p53
and TAp63g (18). Consequently, both N-terminal and SAM-
domain mutations associated with RHS/AEC syndrome
appear to affect transactivation activity by DNp63a isoforms.
A systematic screening of the effects of constructs with N- and
C-terminal mutations on a panel of natural p63 target genes
and in a relevant cell type, such as in keratinocytes, may
give further insight into the precise disease mechanism in
RHS/AEC syndrome. From the present study, we conclude
that the generation of an N-terminally truncated DNp63a
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protein is responsible for causing a Rapp-Hodgkin and AEC
syndrome-like phenotype.
MATERIAL AND METHODS
Clinical study
The index patient of family 1 is a 6-year-old girl, who has a
unilateral cleft lip and palate. She has coarse dry blond hair
and fair skin and there is scaling on the forehead, around
the nipples and on the buttocks. She is anhidrotic. At birth
she had a systolic murmur, but on ultrasound was found to
have a normal cardiac anatomy and the murmur appeared
to be innocent. The index patient’s mother also has ED: her
hair has a coarse texture and a spiky appearance. Her skin is
dry, and she has hypodontia of her primary teeth and her
fingernails are dystrophic. She has anhidrosis on her trunk
and limbs but is able to sweat normally from her palms and
soles. In addition, she has had frequent urinary tract infections.
Unlike her daughter she has secondary hearing loss due to
a malformation of the external ear canal. She also had a
history of a malignant melanoma, which had been excised
from her right hand.
The index patient of family 2 is a 2-year-old boy, who was
born to non-consanguineous parents of Greek-Australian
descent. He has a unilateral cleft of the soft palate and left-
sided ankyloblepharon filiforme. He has sparse eyebrows
and eyelashes in infancy, but no alopecia or dry skin. He
has small nails, which are not dystrophic. He also has hypo-
plastic alae nasi. There are no dental anomalies or delayed
dental eruption.
The patient in family 3 is a 13-year-old girl. She was born
with an absent hard palate in her mouth, ankyloblepharon fili-
forme and an atrial septal defect. As an infant she was prone to
infections, but this later improved. She has upslanting palpeb-
ral fissures, a long nose and a small mouth with a thin upper
lip. She has sparse eyelashes, but extremely thick and bushy
hair, which is easy to brush. Her hands, feet and nails are all
normal.
Mutation analysis
Blood samples and skin samples used in this study were
obtained after written informed consent was obtained.
Genomic DNA was extracted from peripheral blood samples
by a standard salting-out method. All 16 exons of the p63
gene were amplified and sequenced in both directions.
Primers, which were used to amplify the alternative exon 30
and exon 4 are illustrated in Table 1A.
Cell culture
A skin biopsy (4 mm diameter) was taken from the back of the
index patient’s mother. The skin was collected in RMPI
[Gibco] medium with Gentamycin (1:1000) [Gibco], Ampho-
tericin (1:100) [Gibco] and Penicillin/Streptomycin [Gibco].
The biopsy was then trypsinized in 0.25% Trypsin–PBS
[Brunschwig] overnight at 48C following which the upper epi-
dermal layer was separated from the biopsy with tweezers
and the dermal surface was scratched smoothly to release
the keratinocytes. Serum was added to stop the trypsin
activity. Next the solution containing the dermal and epider-
mal components was vortexed at low speed for 1 min. The
dermal parts were removed and the epidermal cells were
added on to irradiated 3T3-J2 cells. Cells were cultured in
Green’s medium: DMEM [Gibco], Ham’s F12 [Gibco] (2:1)
supplemented with 10% fetal bovine serum [Hyclone],
4 mM L-Glutamine [ICN Biomedicals], 100 U/ml penicillin
[Gibco], 100 mg/ml streptomycin [Gibco], 25 mg/ml adenine
[Calbiochem], 5 mg/ml insulin [Sigma], 0.4 mg/ml hydrocorti-
sone [Calbiochem], 1.4 ng/ml triiodothyronine [Sigma],
0.1 nM Cholera toxin [Sigma]. EGF (10 ng/ml) [Sigma] was
added to the medium 3 days after starting the keratinocyte
culture. The medium was refreshed every second day until
the culture reached 80–90% confluence. The primary kerati-
nocyte stocks were stored in liquid nitrogen.
Mouse fibroblast cell line 3T3-J2 was used as a feeder layer
for the keratinocytes in Green’s medium. Pure 3T3-J2 cells
were cultured in DMEM w/o pyruvate [Gibco] containing
10% calf serum supplemented by iron [Hyclone] and 100 U/ml
penicillin [Gibco] and 100 mg/ml streptomycin [Gibco]. 3T3
cells were irradiated at 3500 cGy about 20 h before adding
keratinocytes.
Keratinocytes were cultured at 378C in 5% CO2 in Kerati-
nocyte growth medium (KGM). This medium consists of Ker-
atinocyte Basal Medium, 0.15 mM Ca2þ [Cambrex],
supplemented with 0.1 mM ethanolamine [Sigma], 0.1 mM
phosphoethanolamine [Sigma], bovine pituitary extract
(0.4%) [Bio Whittaker], 10 ng/ml EGF [Sigma], 5 mg/ml
insulin [Sigma], 0.5 mg/ml hydrocortisone [Calbiochem],
100U/ml penicillin [Gibco] and 100 mg/ml streptomycin
[Gibco]. The medium was changed every second day until
the culture reached confluent state.
Transfection conditions
Human osteoblast cell line Saos-2 was used for transient trans-
fections. Saos-2 cells were cultured in DMEM [Gibco] sup-
plemented by 10% fetal calf serum [Sigma], 1%
natrium-puruvate [Gibco], 1% Glutamax-1 [Gibco] and
100 U/ml penicillin [Gibco] and 100 mg/ml streptomycin
[Gibco]. Approximately 1.5  105 Saos-2 cells were seeded
in one well of a 6-well tissue culture plate. Effectene transfec-
tion reagent [Qiagen] was used to transfect the pcDNA3,
pcDNA3_Mm_DNp63a (43) wild-type and its mutant ver-
sions p.Gln11X, p.Gln16X, p.Gln9fsX23, Met26Ile and
double mutant p.Gln11X_Met26Ile, p.Gln16X_Met26Ile and
p.Gln9fsX23_p.Met26Ile constructs into Saos-2 cells. The
same method was used for co-transfections, where either
pcDNA3_DNp63a wild-type was transfected together with
each single mutant (p.Gln11X, p.Gln16X, p.Gln9fsX23)
DNp63a construct or pcDNA3_TAp63g wild-type was trans-
fected together either with wild-type or mutant (p.Gln11X)
pcDNA3_DNp63a construct. The cells were collected 30–48 h
after transfection.
For transfections of the DNp63 truncation mutations (D14,
D26, D43, D61, D79), Saos-2 cells were plated on 18 mm
round glass coverslips and a total of 2 mg plasmid DNA
was transfected using a calcium phosphate precipitation proto-
col (46).
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Luciferase assays
Subconfluent Saos-2 cells were transfected as described above
at a 1:2 ratio between the reporter construct (firefly luciferase
under control of K14 promoter) (kind gift of Dr B. Andersen
and Dr E. Candi) and the wild-type or mutant (p.Gln11X,
p.Gln16X, p.Gln9fsX23) pcDNA3_DNp63a or a combination
of wild-type and mutant vector. In addition, 50 ng of Renilla
luciferase construct was co-transfected in each transfection to
normalize for transfection efficiency. After 30 h the transfection
luciferase activities were measured using a Dual Luciferase
Reporter Assay System [Promega] according to the manufac-
turer’s instructions. The level of activation was calculated in
comparison with transfections with an empty pcDNA3 vector.
Transfections for the TAp63g co-transfection assay were
carried out as described above at a 1:3 ratio between the repor-
ter construct (b-galactosidase reporter under p53 promoter)
and expression construct (pcDNA3_Mm_TAp63g wild-type,
pcDNA3_DNp63a wild-type or p.Gln11X mutant construct,
or in co-transfections TAp63g in combination with DNp63a
wt or mutant). In addition, 5 ng of Renilla luciferase construct
was transfected in each transfection to normalize for transfec-
tion efficiency. After 30 h the transfection b-galactosidase and
luciferase activities were measured using a Luminescent beta-
galactosidase detection kit II [Clontech] and a Renilla Lucifer-
ase Reporter Assay System [Promega] according to the manu-
facturer’s instructions. The level of activation was calculated
in comparison with transfections with an empty pcDNA3
vector. Transactivation assays of the truncation mutations
were carried out as described previously (43).
Mutagenesis
Pathogenic mutations of interest were introduced into the
pcDNA3_DNp63a vector by using QuickChange Site-
Directed Mutagenesis kit [Stratagene] according to the manu-
facturer’s instructions. The p.Gln11X, p.Gln16X, p.Gln9fsX23
and p.Met26Ile mutations were introduced in this vector. The
p.Gln11X, p.Gln16X and p.Gln9fsX23 mutations were also
introduced into pcDNA3_DNp63a_Met26Ile mutation con-
struct to create double mutations. Mutagenesis primers are
shown in Table 1D. The correct sequence of each clone was
determined by direct sequencing of the entire cDNA insert.
N-terminal deletion mutations were introduced into
pcDNA3_Mm_DNp63g vector by using ExSite PCR-based
site-directed mutagenesis procedure [Stratagene] according to
the manufacturer’s instructions. The sequences encoding
amino acids 2–14, 2–26, 2–43, 2–61 and 2–79 (amino acid
numbers referring to DNp63 protein) were removed using oli-
gonucleotides described in Table 1D. The obtained clones
were screened for the presence of the respective deletions by
direct sequencing using primers flanking the deletions.
Sample preparation and immunoblotting
Transfected Saos-2 cells and keratinocytes were harvested in
PBS and centrifuged at 48C at 3000 RPM for 10 min. The
pellet was lysed in lysis buffer containing: 50 mM Tris-HCl
pH 7.8, 10% glycerol [Invitrogen], 0.5% Nonidet-P40
[Brunschwig], and 5 mM Ethylene glycol-bis-tetraacetic acid
(EGTA) [Fluka], and freshly added 10 mM b-mercaptoethanol
[Sigma], 0.5 mM Phenylmethanesulfonyl fluoride [Fluka],
1 mg/ml Pepstatin A [Fluka] and 1 protease inhibitory cock-
tail [Roche], for 20 min on ice. Immunoblotting was per-
formed using the NuPAGEwBis-Tris Pre Cast Gel System
[Invitrogen] following the manufacturer’s instructions.
Samples were run on a 4–12% NuPAGEwBis-Tris gel in
MOPS buffer [Invitrogen]. p63a-Specific polyclonal antibody
H-129 (1:500) [Santa Gruz] was used to detect p63 and a
mouse monoclonal a-Tubulin antibody DM1A (1:5000)
[Abcam] was used as a loading control. Alexa-680
goat-anti-rabbit secondary antibody [Molecular Probes] and
IrDye-800 goat-anti-mouse secondary antibody [Rockland]
Table 1. Oligonucleotide sequences
A GenBank number Exon Forward (50>30) Reverse (50>30) Primer for
NT_005612.15 p63 Exon 30 gcctcctcatgcctatagttg tcttacagccaccacagaaaa PCR, sequencing
NT_005612.15 p63 Exon 4 gatccgtggcttcagcgg aagcccatccttggacttgg PCR, sequencing
B GenBank number Forward (50>30) Reverse (50>30)
AF_075431 DNp63 ctggaaaacaatgcccagac gggtgatggagagagagcat RT-PCR
C GenBank number Forward (50>30) Reverse (50>30)
AF_075431 DNp63 caatgcccagactcaatttagtga tgctggtccatgctgttcag RT-qPCR
AF_075431 DNp63 ttgtacctggaaaacaatgcc tgctggtccatgctgttcag RT-qPCR
AF_075431 p63a tccatggatgatctggcaagt gcccttccagatcgcatgt RT-qPCR
NM_001101 ACTB actggaacggtgaaggtgaca agggacttcctgtaacaacgca RT-qPCR
NM_001002 hARP caccattgaaatcctgagtgatgt tgacaagcccaaaggagaag RT-qPCR
NM_002046 GAPDH tgcaccaccaactgcttagc ggcatggactgtggtcatgag RT-qPCR
D Plasmid Forward (50>30) Reverse (50>30)
pcDNA3_Mm_DNp63a p.Gln11X (c.31C.T) gaaaacaatgcccagacttaatttagtgagccacagt actgtggctcactaaattaagtctgggcattgttttc Mutagenesis
pcDNA3_Mm_DNp63a p.Gln16X (c.46C.T) caatttagtgagccatagtacacgaacctgg ccaggttcgtgtactatggctcactaaattg Mutagenesis
pcDNA3_Mm_DNp63a p.Gln9Xfs23 (c.26delA) ctggaaaacaatgcccgactcaatttagtgag ctcactaaattgagtcgggcattgttttccag Mutagenesis
pcDNA3_Mm_DNp63a p.Met26Ile (c.78G.A) gctcctgaacagcatagaccagcagattcag ctgaatctgctggtctatgctgttcaggagc Mutagenesis
pcDNA3_Mm_DNp63g D14 ccacagtacacgaacctggggctcc catccgcggggcaggggtcccggaa Mutagenesis
pcDNA3_Mm_DNp63g D26 gaccagcagattcagaacggctcc catccgcggggcaggggtcccggaa Mutagenesis
pcDNA3_Mm_DNp63g D43 cacgcacagaatagcgtgacggcgc catccgcggggcaggggtcccggaa Mutagenesis
pcDNA3_Mm_DNp63g D61 tttgatgccctctctccatcccctg catccgcggggcaggggtcccggaa Mutagenesis
pcDNA3_Mm_DNp63g D79 cacagcttcgatgtgtccttccagc catccgcggggcaggggtcccggaa Mutagenesis
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were both used in 1:5000 dilution. The signal detection was
performed by Odyssey scanner [Licor].
RNA isolation
Keratinocytes were cultured in KGM and harvested either at
confluent state or after 48 h differentiation. Total RNA iso-
lation was performed using the RNeasy mini kit [Qiagen]
according the manufacturer’s instructions. RNA was treated
with DNase I while bound to the RNeasy column to remove
residual traces of genomic DNA [Qiagen]. The integrity of
the RNA was assessed on an agarose gel, and the concen-
tration and purity were determined with a ND-1000 spectro-
photometer [Nanodrop].
Reverse transcriptase PCR
Two mg of total RNA was transcribed into cDNA as described
earlier (47). cDNA was amplified with a forward primer
specific to alternative exon 30 of p63 gene and a reverse
primer specific to exon 4 with a total number of 35 cycles.
Primer sequences are in Table 1B. The RT-PCR product
was electrophoresed in an agarose gel and purified using the
Qiaquick gel extraction kit [Qiagen]. This cDNA product
was sequenced with reverse primer by using a 3730 DNA ana-
lyzer from Applied Biosystems.
Quantitative PCR
qPCR was performed on the iQ-apparatus [MyiQ single-color
real-time detection system (Biorad)] by using iQ SYBRw
Green Supermix [Biorad] according to the manufacturer’s pro-
tocol. All primer pairs were designed such that they cover
either separate exons or that one is spanning an exon-exon
boundary. All primers were validated in triplicate by use of
serial cDNA dilutions, and were confirmed for 100+ 5% effi-
ciency. Differences in the expression of a gene of interest
between two samples were calculated by 2DDCt method
(48,49). To normalize the amount of cDNA we used three
housekeeping genes: beta-actin (ACTB), hARP (human
acidic ribosomal protein) and GAPDH (glyceraldehyde-3-
phosphate dehydrogenase protein). All samples were used in
duplicate and housekeeping genes were run on the same
plate in the iQ-apparatus as the gene of interest. Primer
sequences are provided in Table 1C.
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